Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role  Takeda Pharmaceuticals  Fee  Investigatory & PI Boland  Janssen Biotech, Inc.  Fee  Investigator

Chu  Promius Pharma, LLC  Honorarium  Advisory Board, Speaking  Boehringer-Ingelheim, Celgene Corporation, Celltrion, Enterome, Genetech, Medimmune, Merck & Co,  Honorarium  Consultant/Advisor Pfizer, Protagonist, Second Genome, Seres, Takeda  Consultant/Advisor,  Amgen, Ferring  Honorarium Speaker's Bureau Colombel  Consultant/Advisor,  AbbVie, Inc.  Honorarium Research Support, Speaker  Conusltant/Advisor,  Janssen & Janssen, Shire  Honorarium Research Support

 Genefit, Intestinal Biotech Development   Stock Options

Coyle  None  N/A  N/A

 AbbVie, Inc.  Honorarium  Speaker, Advisory Board

Evans  Takeda Pharmaceuticals, UCB, Inc.  Honorarium  Speaker

 IBDSF  Honorarium  Medical Advisory Board  AbbVie Inc., Amgen Inc., AstraZeneca/MedImmune Ltd., Atlantic Pharmaceuticals Ltd., Boehringer- Ingelheim, Celgene Corporation, Celltech, Genentech Inc/Hoffmann-La Roche Ltd., Gilead Sciences Inc.,  Research Grant  Grant/Research Support GlaxoSmithKline (GSK), Janssen Research & Development LLC., Pfizer Inc., Receptos Inc. / Celgene Feagan International, Sanofi, Santarus Inc., Takeda Development Center Americas Inc., Tillotts Pharma AG, UCB  Abbott/AbbVie, Inc., Actogenix, Akros, Albireo Pharma, Allergan, Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc., Avir Pharma, Baxter  Consulting Fee  Consultant Healthcare Corp., Biogen Idec, Boehringer-Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene,

Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, Galapagos, GiCare Pharma, Gilead, Given Imaging Inc., GSK, Inception IBD Inc, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestles, Novonordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Roche/Genentech, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd., Warner-Chilcott, Wyeth, Zealand, Zyngenia  Abbott/AbbVie, Inc., JnJ/Janssen,  Speaker fee  Speakers Bureau Takeda, UCB Pharma  Abbott/AbbVie, Inc., Allergan, Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Centocor Inc., Elan/Biogen, Ferring,  Member, Scientific Galapagos, Genentech/Roche,  Other Financial benefit Advisory Board JnJ/Janssen, Merck, Nestles, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Takeda, Teva, TiGenix, Tillotts Pharma AG, UCB Pharma  Officer – Robarts Clinical Trials Inc,  Member, Board of  Other Financial benefit Western University, London Directors  Consulting/Speakers  AbbVie, Inc.  Honorarium Bureau/Advisory Board Ha  Pfizer  Honorarium  Advisory Board

Konijeti  None  N/A  N/A

 Gilead  Honorarium  Speakers Bureau  Speakers Bureau, Nguyen  AbbVie, Inc.  Honorarium Consultant  Nestle Nutrition Institute  Honorarium  Consultant  Atlantic, Janssen, Merck, Pfizer, Salix,  Grant/Research  Research Seres, Takeda Support Pardi  Assembly Bioscience, C3 Jian, Ferring, Janssen, Nestle, Merck, Otsuka, Salix,  Fee  Consulting Seres Read  None  N/A  N/A

 Janssen Biotech, Inc.  Research Funding  Consultant, Advisor  AbbVie, Inc., Actavis, Salix Sandborn Pharmaceuticals, Ltd., Shire, Takeda  Honorarium  Consultant, Advisor Pharmaceuticals, UCB, Inc.  Amgen, Inc., Genentech, Pfizer, Inc.,  Research Funding  Consultant, Advisor Prometheus Laboratories, Inc.

Singh  AbbVie, Inc., Pfizer, Inc.  Grants  Research

Taplitz  None  N/A  N/A

Worsey  None  N/A  N/A CME Review  None  N/A  N/A Committee Scripps Conference  None  N/A  N/A Services & CME

Glossary of Terms Commercial Interest The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. Financial Relationships Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, Honorarium, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner. Relevant Financial Relationships ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Conflict of Interest Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.